Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1996-08-22
1998-07-14
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K 31155
Patent
active
057805130
ABSTRACT:
A method for the treating an individual afflicted with a disease condition mediated by IL-1 bioactivity is disclosed. The method comprises administering an effective amount of the NOS inhibitor, aminoguanidine, to an individual.
REFERENCES:
Medline Abstract 9 512 7921, 1994. Reimers et al.
Medline Abstract 96132680, 1995, Jo et al.
Dinarello, Modalities for reducing interleukin 1 activity in disease, Trends in Pharmaceut. Sci. 14:155-159, 1993.
Dinarello, Interleukin-1, Adv. Pharmacol. 25:21-51, 1994.
Corbett et al., Does Nitric Oxide Mediate Autoimmune Destruction of .beta.-Cells?, Diabetes 41:897-903, 1992.
Okusawa et al., Interleukin 1 Induces a Shock-like State in Rabbits, J. Clin. Invest. 81:1162-1172, 1988.
Fischer et al., Comparison between effects of interleukin-1.alpha. administration and sublethal endotoxemia in primates, Am. J. Physiol. 261:R442-R452, 1991.
Fischer et al., Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial, Crit. Care Med. 22:12-21, 1994.
Rambaldi et al., Modulation of Cell Proliferation and Cytokine Production in Acute Myeloblastic Leukemia by Interleukin-1 Receptor Antagonist and Lack of its Expression by Leukemic Cells, Blood 78:3248-3253, 1991.
Estrov et al., Suppression of Chronic Myelogenous Leukemia Colony Growth by Interleukin-1 (IL-1) Receptor Antagonist and Soluble IL-1 Receptors: A Novel Application for Inhibitors of IL-1 Activity, Blood 78:1476-1484, 1991.
Rothwell et al., Involvement of Interleukin-1 and Lipocortin-1 in Ischaemic Brain Damage, Cerebrovasc. Brain Metab. Rev. 5:178-198, 1993.
Mrak et al., Glial Cytokines in Alzheimer's Disease: Review and Pathogen Iplications, Human Pathology 26:816-823, 1995.
Kimble et al., Persistent Bone-Sparing Effect of Interleukin-1 Receptor Antagonist: A Hypothesis on the Role of IL-1 in Ovariectomy-Induced Bone Loss, Calcif. Tissue Int. 55:260-265, 1994.
Bredt et al., Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme, PNAS, USA 87:682-685, 1990.
Arend et al., Inhibition Of The Production And Effects Of Interleukin-1 And Tumor Necrosis Factor .alpha. In Rheumatoid Arthritis, Arthritis & Rheumatism, 38:151-160, 1995.
Henricson et al., An Interleukin-1 Receptor Antagonist Blocks Lipopolysaccharide-Induced Colony-Stimulating Factor Production and Early Endotoxin Tolerance, Infect. Immun. 59: 1188-1191, 1991.
Mazzei et al., Purification and characterization of a 26-kDa competitive inhibitor of interleukin 1, Eur J. Immunol. 20:683-689, 1990.
Seckinger et al., A Urine Inhibitor of Interleukin 1 Activity That Blocks Ligand Binding, Ann. Inst. Pasteur/Immunol. 139:1546-1549, 1987.
Bagby et al., Interleukin 1-dependent Paracrine Granulopoiesis in Chronic Granulocytic Leukemia of the Juvenile Type, J. Clin. Invest. 82:1430-1436, 1988.
Estrada et al., Nitric Oxide Mediates Tumor Necrosis Factor-.alpha. Cytotoxicity In Endothelial Cells, Biochem. Biophys. Res. Commun. 186:475-482, 1992.
Michetti et al., Reversible Inactivation of Calpain Isoforms By Nitric Oxide, Biochem. Biophys. Res. Comm. 207:1009-1014, 1995.
Gearing et al., Production and Assay of the Interleukins, J. Immun. Methods, 83:1-27, 1985.
Remvig, Cellular cytokine bioassays in interleukin-1 quantitation, Dan. Med. Bull. 40:255-265, 1993.
Hill et al., Nitric Oxide Production by the Rat Insulinoma Cell Line, RINm5F, Is Specific for IL-1: A Spectrophotometric IL-1 Bioassay, Analytical Biochemistry, 236:14-19, 1996.
Dinarello, The interleukin-1 family: 10 years of discovery, FASTEB J., 8:1314-1325, 1994.
Miller et al., The IL-1 .beta. Converting Enzyme as a Therapeutic Target, Ann. NY Acad. Sci., 696:133-148, 1993. Biological Fluids, Anal. Biochem. 126:131-138, 1982.
Beckerman et al., Release of Nitric Oxide during the T Cell-Independent Pathway of Macrophage Activation, J. Immunol. 150:888-895, 1993.
Stuehr et al., Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs, FASEB J. 5:98-103, 1991.
Corbett John A.
Hill Jeanette R.
McDaniel Michael L.
Fay Zohreh
Washington University
LandOfFree
Method of inhibiting the release of bioactive IL-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting the release of bioactive IL-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting the release of bioactive IL-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1882264